Glenmark Pharmaceuticals shares rise after US FDA approval for Fluticasone nasal spray

cals Glenmark Pharmaceuticals climbed about 1.4% in early trade on Thursday after the company received US Food and Drug Administration (FDA) approval for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. On the National Stock Exchange, the stock was trading 1.43% higher at Rs 2,278.60 around 9:35 am. The product is bioequivalent and therapeutically equivalent to Flonase Nasal Spray and will be marketed in the United States by Glenmark Pharmaceuticals Inc., USA. According to IQVIA data for the 12 months ended June 2026, the Flonase Nasal Spray market generated approximately $295.2 million in annual sales. Marc Kikuchi, President & Business Head, North America at Glenmark, said the approval expands the company’s respiratory portfolio in the US and strengthens its commitment to offering quality, affordable treatment options for patients and healthcare providers.